News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Sunovion Presents Data from Pivotal Phase 3 Study of Apomorphine Sublingual Film (APL-130277)

(June 25, 2018) – Sunovion Pharmaceuticals today presented the positive results of its pivotal, Phase 3, randomized, double-blind, placebo-controlled trial, CTH-300. This study evaluated apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease (PD) who experience motor fluctuations (OFF episodes), including those who experience early morning OFF episodes. The study results were presented as a late-breaking abstract poster at the 2nd Pan American Parkinson’s Disease and Movement Disorders Congress (MDS-PAS) in Miami, Florida. Read more